Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 3, 2013, Pages 693-704

  Pérez Ruixo, Carlos ^a   Valenzuela, Belén ^b   Peris, José Esteban ^a   Bretcha Boix, Pedro ^b   Escudero Ortiz, Vanesa ^b   Farré Alegre, José ^b   Pérez Ruixo, Juan José ^c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b USP Hospital San Jaime   (Spain)

^c AMGEN   (Spain)

Author keywords

Hyperthermic intraperitoneal chemotherapy (HIPEC); Oxaliplatin; Peritoneal carcinomatosis; Population pharmacokinetics

Indexed keywords

GLUCOSE; ICODEXTRIN; ISOTONIC SOLUTION; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BOOTSTRAPPING; CANCER CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PERITONEAL FLUID LEVEL; FEMALE; HUMAN; HYPERTHERMIC THERAPY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NONPARAMETRIC TEST; POPULATION RESEARCH; PRIORITY JOURNAL; STATISTICAL MODEL; TREATMENT DURATION; AGED; ALGORITHM; ANALYSIS OF VARIANCE; CARCINOMA; COMPUTER PROGRAM; HALF LIFE TIME; INTRAPERITONEAL DRUG ADMINISTRATION; LAPAROTOMY; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERITONEUM; PERITONEUM TUMOR; POPULATION; SOLUTION AND SOLUBILITY;

AGED; ALGORITHMS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; HALF-LIFE; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAPERITONEAL; LAPAROTOMY; MALE; MIDDLE AGED; MODELS, STATISTICAL; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PERITONEUM; PHARMACEUTICAL SOLUTIONS; POPULATION; SOFTWARE;

MLCS; MLOWN;

EID: 84875857787     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2060-2     Document Type: Article

References (40)

1. Spiliotis JD (2010) Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure. Hepatogastroenterology 57:1173-1177
2. Valenzuela B, Nalda-Molina R, Bretcha-Boix P et al (2011) Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis. AAPS J 13:72-82
3. Elias D, Lefevre JH, Chevalier J et al (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27:681-685
4. Di Giorgio A, Naticchioni E, Biacchi D et al (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113:315-325
5. Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737-3743 (Pubitemid 46606227)
6. Yang XJ, Huang CQ, Suo T et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18:1575-1581
7. Cao C, Yan TD, Black D et al (2009) A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surf Oncol 16:2152-2165
8. Sugarbaker PH (1998) Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 14:254-261 (Pubitemid 28146518)
9. de Bree E, Tsiftsis D (2007) Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Results Cancer Res 169:39-51
10. Atallah D, Marsaud V, Radanyi C et al (2004) Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines. Int J Hyperthermia 20:405-419 (Pubitemid 38832570)
11. Elias D, El Otmany A, Bonnay M et al (2002) Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:267-272 (Pubitemid 34704979)
12. Culy CR, Clemett D, Wiseman LR (2000) Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60:895-924
13. Elias D, Sideris L (2003) Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin North Am 12:755-769 (Pubitemid 36920097)
14. Massari C, Brienza S, Rotarski M et al (2000) Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 45:157-164 (Pubitemid 30090247)
15. Ferron G, Dattez S, Gladieff L et al (2008) Pharmacokinetics of heated intraperitoneal oxaliplatin. Cancer Chemother Pharmacol 62:679-683
16. Mohamed F, Sugarbaker PH (2003) Carrier solutions for intraperitoneal chemotherapy. Surg Oncol Clin North Am 12:813-824 (Pubitemid 36920101)
17. Bretcha-Boix P, Farré-Alegre J, Sureda M et al (2010) Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies. Clin Transl Oncol 12:437-442
18. Sugarbaker PH (1998) Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Sem Surg Oncol 14:254-261 (Pubitemid 28146518)
19. Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29-42
20. Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359-374
21. Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147 (Pubitemid 30036347)
22. Dominici C, Petrucci F, Caroli S et al (1989) Pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors. J Clin Oncol 7:100-107 (Pubitemid 19089087)
23. Sooriyaarachchi M, Narendran A, Gailer J (2011) Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro. Metallomics 3:49-55
24. Alimonti A, Petrucci F, Dominici C, Caroli S (1987) Determination of Pt in biological samples by inductively coupled plasma atomic emission spectrometry (ICP-AES) with electrothermal vaporization (ETV). J Trace Elem Electrolytes Health Dis 1:79-83
25. Beal SL, Sheiner LB, Boeckman AJ (1989-2006) NONMEM users guides. ICON Development Solutions, Ellicott City
26. Marzo A, Monti NC, Vuksic D (1999) Experimental, extrapolated and truncated areas under the concentration-time curve in bioequivalence trials. Eur J Clin Pharmacol 55:627-631
27. Bland JM, Altman DG (1996) Transformations, means, and confidence intervals. BMJ 312:1079 (Pubitemid 26125136)
28. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biophar 20:511-528 (Pubitemid 23034413)
29. Manly BFJ (1997) Randomization, bootstrap and Monte Carlo methods in biology. Texts in Statistical Science. Chapman and Hall, London
30. Wählby U, Jonsson EN, Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231-252 (Pubitemid 32643366)
31. Efron B, Tibshirani R (1993) An introduction to the bootstrap. Chapman and Hall, London
32. Brendel K, Comets E, Laffont C et al (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23:2036-2049
33. Post TM, Freijer JI, Ploeger BA et al (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35:185-202
34. Hooker AC, Staatz CE, Karlsson MO (2007) Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 24:2187-2197 (Pubitemid 350060706)
35. Brouwers EE, Huitema AD, Beijnen JH et al (2008) Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 17(8):7
36. Stewart JH 4th, Shen P, Russell G et al (2008) A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol 15:2137-2145
37. Elias D, El Otmany A, Bonnay M et al (2002) Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 63:346-352 (Pubitemid 36151527)
38. Litterst CL, Torres LJ, Sikic BI (1980) Absorption of antineoplastic drugs following large volume administration to rats. Cancer Treat Rep 66:147-155
39. Kusamura S, Dominique E, Baratti D et al (2008) Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 98:247-252
40. Pestieau SR, Schnake KJ, Stuart OA et al (2001) Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol 47:269-276 (Pubitemid 32640763)